Skip to content
  • Newsroom
  • Events
  • Contact
  • Home
  • Patients

    I need help with...

    • Understanding pelvic masses

      What is an adnexal mass and does it mean I have cancer?

    • Treatment plan options

      What testing is available to help map my treatment plan?

    • What to expect

      What do I need to know if my doctor orders one of your test kits?

    • Ongoing support

      Where can I turn for additional support?

    About Our tests

    Which test should I use?

    How do I tell my provider to order a test?

    Patient Resources

    Insurance & Billing

    Financial Assistance

    Pay a Bill

    Contact Us

  • Providers

    I need help with...

    • Assessing a pelvic mass

      What are the testing options available for pelvic masses?

    • Testing an indeterminate or likely benign pelvic mass

      Which test should I use if an unknown mass has been identified?

    • Testing a pelvic mass with planned surgery

      Which test should I use to assess my risk of malignancy before surgery?

    • How does the test work?

      What additional services do you provide?

    Order Test Kits

    Ova1Plus®

    OvaWatch®

    Scientific Publications

    FAQs

    Clinical Studies

    Your patient may qualify for a clinical trial, learn more →

    Provider Resources

    Order Test Kits

    Order Patient Materials

    Download Test Requisition Form

    Insurance & Billing

    Provider Events

  • Our Products
    • OvaWatch®
    • Ova1Plus®
  • About Us
    • About Us
    • Leadership
    • Careers
  • Research & Development
    • Pipeline
    • Clinical Study
    • Research and Professional Guidelines
  • Investors
    • Investor Overview
    • News
    • Events & Presentations
    • SEC Filings
    • Stock Information
    • Corporate Governance

Association for Molecular Pathology (AMP)

By Gina | November 19, 2024

Vancouver, CA

Recent Posts

  • Aspira Women’s Health Announces Appointment of Ellen Beausang to the Board of Directors
  • Aspira Women’s Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations
  • Aspira Women’s Health Announces Appointment of Dr. Sandra Milligan as Interim CEO
  • Aspira Women’s Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award
  • Aspira Women’s Health Reports Selected Third Quarter 2024 Financial Results

Recent Comments

    Archives

    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024

    Categories

    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Search

    Footer

    Have a question?

    Tel: 844-ASPIRA1 (844-277-4721)

    Fax: 866-283-3634

    12117 Bee Caves Road
    Building III, Suite 100
    Austin, TX 78738

    Investors

    Investor Overview

    Events & Presentations

    SEC Filings

    Corporate Governance

    Stock Information

    Providers & Practices

    Provider Overview

    Research and Professional Guidelines

    Clinical Studies

    Pipeline

    Patients & Individuals

    Patient Overview

    Insurance & Billing

    Bill Pay

    Resources

    News

    Educational Events

    FAQs

    About

    About Aspira

    Leadership

    Licensure & Legal

    Code of Conduct

    Aspira Synergy

    © 2023-2025 Aspira Women's Health. All Rights Reserved.

    Privacy Policy. Terms of Use.

    • Home
    • Patients
    • Providers
    • Our Products
      • OvaWatch®
      • Ova1Plus®
    • About Us
      • Our Story
      • Leadership
      • Careers
    • Research and Development
      • Pipeline
      • Clinical Study
      • Research and Professional Guidelines
    • Investors
      • Investor Overview
      • News
      • Events & Presentations
      • SEC Filings
      • Stock Information
      • Corporate Governance